Upgrade to Chrome Upgrade to Firefox Upgrade to Internet Explorer Upgrade to Safari

Meet the Management Team

Speak to our team

HEOR Ltd is lead by its Founders and Chiefs – Phil McEwan and Jason Gordon and supported by our experienced teams of Directors and Senior Managers and over 90 Consulting and Research Professionals.

We provide a supportive culture focused on individual’s development and satisfaction; consequently, we have a high rate of staff tenure. Our staffing model is designed to recruit and retain staff that provide a powerful mix of technical and research excellence, commercial awareness, and second to none deliverables. Our rationale is to have in place the resources required to deliver exceptional quality and innovation that promotes the appropriate use of technologies and maximises their commercial opportunity.

Directors

Supporting Phil and Jason is our Operations Director, Rachel Livermore, and our Director of Value and Access, Nick Bruce. Our HEOR Germany team is led by Technical Director, Volker Foos.

Phil McEwan

Chief Executive Officer, PhD

Read Biography

Jason Gordon

Chief Commercial Officer, PhD

Read Biography

Senior Managers

Our Senior Management is made up of Ian Jacob (Health Economics), Daniel Sugrue (Medical Writing), Beverley Jones (HTA), Carmen Tsang (Data Science and Analytics), Kevin Cadwell (Systematic Reviews) and Hannah Matthews (Commercial Manager)

Training and Education

Economic evaluations of healthcare interventions routinely focus on population level cost-effectiveness analyses to support reimbursement decisions; the so-called ‘Fourth Hurdle’. Yet what is informative at the policy level does not always translate meaningfully to the local population or individual patient level.Population level analyses consider the ‘average patient’, while local payers and prescribers work with a group of individual patients with specific characteristics and health challenges. Translating the findings of policy level analyses to individual patients requires a full understanding of drivers of economic value and consequent affordability. Demonstrating value to payers and prescribers is increasingly recognised as the ‘Fifth Hurdle’.

View Case Study